October 2025
1. DE KOFF EM, van Andel H, de Jong HK, van der Kooi AJ, et al
   Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report.
   Antivir Ther. 2025;30:13596535251385624.
   

   >> Share

   
   June 2025
2. GAO Y, Ji W, Chen Q
   The diagnostic significance of the C-reactive protein (CRP) in HIV/TB coinfection: A systematic review and meta-analysis.
   Antivir Ther. 2025;30:13596535251345870.
   

   >> Share

   
   
3. VAN HEMELRYCK S, Van Landuyt E, Deleu S, Leopold L, et al
   Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion: Bioequivalence versus separate agents in healthy participants and acceptability in children living with human immunodeficiency virus-1.
   Antivir Ther. 2025;30:13596535251349336.
   

   >> Share

   
   April 2025
4. ELEJE GU, Usman HA, Onubogu CU, Fiebai PO, et al
   Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort study.
   Antivir Ther. 2025;30:13596535251333259.
   

   >> Share

   
   
5. PALLANZA M, Thoueille P, Briki M, Alves Saldanha S, et al
   Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.
   Antivir Ther. 2025;30:13596535251335080.
   

   >> Share

   
   
6. LABATE L, Rossetti B, Russo C, Cassol C, et al
   Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database.
   Antivir Ther. 2025;30:13596535251317054.
   

   >> Share

   
   February 2025
7. PICKERING RT, Asundi A, Olson A, Soden K, et al
   Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir.
   Antivir Ther. 2025;30:13596535251314571.
   

   >> Share

   
   December 2024
8. PASSEROTTO RA, Lamanna F, Salvo PF, Iannone V, et al
   Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort.
   Antivir Ther. 2024;29:13596535241306467.
   

   >> Share

   
   April 2024
9. VAN HEMELRYCK S, Van Landuyt E, Hufkens V, Vanveggel S, et al
   Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged >/=6 to <12 years, using matching placebo tablets: A ran
   Antivir Ther. 2024;29:13596535241248282.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share